Company invites individual and institutional investors as well as advisors to attend interactive real-time presentation at VirtualInvestorConferences.com
NEW YORK and VANCOUVER, British Columbia, March 2, 2015 /PRNewswire/ -- InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company specializing in the development of cannabinoid based therapies, today announced that Craig Schneider, Chief Executive Officer, will provide a company overview during a live webcast at VirtualInvestorConferences.com.
DATE: Thursday, March 5, 2014
TIME: 1:15pm ET
LINK: http://VirtualInvestorConferences.com > click the red "register/ watch event now" button
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as InMed's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
Amy Wheeler (Media)
Bradley H. Smith
Director of Marketing
IR and Compliance Services
SOURCE InMed Pharmaceuticals, Inc.